Vivos (RDGL) Non-Current Assets (2010 - 2025)

Vivos (RDGL) reported Non-Current Assets of $216514.0 for Q4 2025, up 32263.83% sequentially from $669.0 in Q3 2018.

Vivos (RDGL) Non-Current Assets (2010 - 2025) Analysis & Trends

Vivos (RDGL) has 10 years of Non-Current Assets data on file, last reported at $216514.0 in Q4 2025.

For the quarter ending Q4 2025, Non-Current Assets changed N/A year-over-year to $216514.0; the trailing twelve-month figure through Dec 2025 stood at $216514.0 (changed N/A YoY), and the FY2025 full-year result was $216514.0, changed N/A from the prior year.
Non-Current Assets advanced to $216514.0 in Q4 2025, from $669.0 in the prior quarter.
In the past five years, Non-Current Assets ranged from a high of $216514.0 in Q4 2025 to a low of $216514.0 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Assets (Qtr)
1	Abbott Laboratories	182.32 Bn	175.02 Bn	6.27 Bn	84.92 Bn
2	Stryker	128.75 Bn	125.88 Bn	3.81 Bn	32.95 Bn
3	Medtronic	107.83 Bn	98.61 Bn	6.41 Bn	68.24 Bn
4	Boston Scientific	67.61 Bn	66.15 Bn	3.61 Bn	35.67 Bn
5	Edwards Lifesciences	48.13 Bn	44.45 Bn	1.29 Bn	7.09 Bn
6	Dexcom	28.26 Bn	27.14 Bn	750.30 Mn	2.30 Bn
7	GE HealthCare Technologies	27.78 Bn	25.50 Bn	1.98 Bn	26.70 Bn
8	Smith & Nephew	26.99 Bn	26.41 Bn	-	6.35 Bn
9	Koninklijke Philips	23.92 Bn	20.80 Bn	2.07 Bn	20.47 Bn
10	Vivos	27.16 Mn	25.60 Mn	-3,105.00	216,514.00

Download Data